The initial success of the copyright undeniably revolutionized the pharmaceutical landscape, but placing funds in companies heavily reliant on unbranded versions presents a challenging picture. Although early profits were substantial, the end of patents and the emergence of less expensive alternatives have diminished the customer base. Consequen… Read More